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ABSTRACT
In this paper, we describe a simple, rapid, specific, sensitive, and reliable method, the FICP method (Fluorescence 
Immunoassay for Cellular Protein detection) which is readily applicable to the detection of proteins directly on cells 
cultured in 96-well plates. In order to illustrate this method, we report on the detection of two different proteins, the 
cell cycle proteins cyclin D1 and p21
CIP1/WAF1, in untreated and 2-cyclopenten-1-one treated breast cancer cells. When the 
FICP method was compared with Western blot procedure, FICP was found to be superior for many characteristics. By 
using this method, we were able to quantify biological effects of a specific compound on protein levels in non-lysed 
cells and perform statistical analysis. Therefore, we believe this screening assay could be very useful for detecting 
poorly expressed proteins and for drug development.
INTRODUCTION
One of the main limitations to the development of drugs is 
the availability of a rapid, quantitative and sensitive assay 
for cellular protein detection (1). The presence of specific 
proteins in tissues or cells has been traditionally detected 
by biochemical methods such as Western immunoblotting 
or   immunological   methods   such   as   ELISA   and 
immunocytochemistry. Recently, proteomic technologies 
have created new possibilities in the discovery of novel 
drug targets and have been applied to study numerous 
protein   interactions,   to   measure   binding   affinities, 
specificities, and levels of protein expression in various 
preparations, and in the investigation of various disorders 
(2-6). However, the use of protein microarrays to study 
protein abundances or protein-protein interactions in the 
complex cellular environment is still under development 
(7).
There are few high-throughput methods for the analysis 
of gene expression and function directly in mammalian 
cells  and high-throughput technologies for quantitative 
cell   biology   are   still   at   the   developmental   stage  (8). 
Recently, some cell (9) and tissue microarrays (10) have 
emerged for the study of gene activity, protein expression, 
and cell-surface exploration and offer the potential to 
accelerate high-throughput functional genetic studies. A 
new   focus   in   the   cell   microarray   field   has   been   the 
adaptation of cell arrays for RNAi in a high-throughput 
format (11, 12) and the development of a new protein 
microarray platform, Dissociable Antibody MicroArray 
(DAMA)   staining   allowing   global   analysis   of   protein 
expression and subcellular localization (13). Although cell 
microarray technology has many possible experimental 
uses, several technical limitations need to be addressed 
before its full potential can be fulfilled (8, 12, 14). The 
main obstacles are the creation of the DNA constructs and 
the production of diverse libraries of RNAi types from 
which slides are printed, and the efficiency of nucleic acid 
delivery in different cell lines and primary cells that are 
difficult to transfect. Also, the most pressing need in cell 
microarrays is continued improvement in the flexibility, 
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accuracy and speed of image analysis and in the tools for 
analyzing the resulting quantitative data.
In this study, we describe a fluorescence immunoassay for 
cellular protein detection (FICP) in microwell plates that 
can be used to perform drug screening rapidly, at a low 
cost, and with specificity for the targeted proteins. We 
have   adapted   standard   techniques   for 
immunofluorescence microscopy (15) to the use of a 96-
well microplate for the screening of drug effects on a 
specific   protein.   The   assay   procedure   allows   rapid 
screening of proteins variation in many cell samples by 
measuring protein abundance/well. 
In order to demonstrate the full potential of this method, 
we   have   used   an   experimental   model   based   on 
cyclopentenone   prostaglandins.   Cyclopentenone 
prostaglandins (PGA1, PGA2, PGJ2 and their metabolites) 
are potent inhibitors of tumor cell proliferation  in vitro 
and   are   able   to   suppress   tumorigenicity  in   vivo  by 
regulating the expression of a variety of stress-induced 
and  cell cycle related  genes (16).  2-Cyclopenten-1-one 
(cyclopentenone) causes cell cycle arrest in G1 by down-
regulating   cyclin   D1   gene   expression   and   cyclin 
dependent   kinase   4   (CDK4)   and   inducing   the   CDK 
inhibitor p21
CIP1/WAF1 (17-19). Recently, MCF-7 cells treated 
with cyclopentenone were found to arrest not only in G1 
but also at the G2 -M phase via inhibition of cyclin B1 
expression and aurora-B kinase activity (20). We have 
found that cellular distribution of lipoplex DLS-siRNAs 
targeting cyclin D1 mRNA in MCF-7 cells varied with 
cyclopentenone   or   17β-estradiol   treatments   (21).   The 
amount of rhodamine-labeled siRNAs present in cells 
treated with cyclopentenone was lower when compared to 
untreated cells. In contrast, in cells treated with 17β-
estradiol   rhodamine   fluorescence   was   more   intense 
indicating   that   more   siRNAs   were   present   when 
compared   to   untreated   MCF-7   cells.   We   believe   that 
siRNAs   following   delivery   by   DLS   might   localize 
specifically to their mRNA targets in the cells and that the 
variations in the amount of siRNAs present in cells might 
reflect the effects of cyclopentenone or 17β-estradiol on 
cyclin D1 gene expression. In the present study, we used 
the microwell cell-based fluorescence immunoassay FICP 
to demonstrate at the protein level that cyclopentenone 
represses the expression of cyclin D1 and induces the 
expression of the CDK inhibitor p21
CIP1/WAF1 in MCF-7 cells. 
MATERIALS AND METHODS
Cell culture
The human breast carcinoma cancer cell line MCF-7 was 
purchased from the American Type Culture Collection 
and plated in 25 cm
2  flasks. Cells were cultivated in 
Dulbecco’s   Modified   Eagle   Medium   (Gibco-Invitrogen, 
Grand   Island,   N.Y.)   supplemented   with   2   mM   L-
glutamine (Sigma-Aldrich, St-Louis, MO) and gentamicin 
50 ug/mL (Gibco- Invitrogen, Grand Island, NY) in the 
presence   of   10%   fetal   bovine   serum   (BioMedia, 
Drummondville,   QC,   Canada).   Cells   at   exponential 
growth were rinsed with PBS before being treated with 
trypsin-EDTA (Gibco-Invitrogen, Grand Island, N.Y.) and 
centrifuged for 10 minutes at 1100 r.p.m. The pellet was 
resuspended in complete culture medium and plated in 
black 96-well microplates with clear bottoms (Corning 
Costar, Fisher Scientific, USA ) at a density of 10,000 cells 
per well. Cells were incubated 24 hours at 37°C in a 5% 
CO2 atmosphere to allow them to adhere to the bottom of 
the well. Then, cells were treated with different doses of 2-
cyclopenten-1-one diluted in sterile water (Sigma-Aldrich, 
St-Louis MO) for 4 hours.
Microwell fluorescence immunoassay
Cells were fixed directly in the 96-well microplate by 
using cold methanol. Culture medium was removed by 
pipetting and cells were washed gently twice with 100 μL 
Dulbecco’s Phosphate Buffered Saline (PBS) with MgCl2 
and CaCl2 pH 7.4 (Gibco-Invitrogen, Grand Island, NY) by 
pipetting carefully to do not disturb or damage the layer 
of cells. To fix the cells, a volume of 100 μL of -20°C 
methanol was added and the microplate was put on ice 
for 10 minutes. Cells were then washed twice with 100 μL 
of PBS at 22°C.
To permeabilize the fixed cells, a solution (100 μL/well) of 
0.5% Triton X-100 (Sigma-Aldrich, St-Louis, MO) in PBS 
was added, and cells were incubated for 12 minutes on 
ice. After rinsing twice with PBS at 22°C, cells were 
incubated at 22°C for 5 minutes in the presence of 100 μL 
of a 22°C solution of 5% serum in PBS, and rinsed with 
100 μL of a 22°C solution of 0.2% gelatin (Sigma-Aldrich, 
St-Louis, MO) in PBS for 5 minutes. These steps make 
possible prevention of random non-specific binding of 
antibodies and avoid false positive results.
A volume of 40 μL (4 μg/mL) of mouse monoclonal anti-
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cyclin   D1   antibody   (1:50   in   the   blocking   buffer 
PBS/Gelatin; clone A-12, Santa Cruz, CA) was added, and 
cells were incubated for 1 hour at 37°C. As negative 
controls, primary antibody was replaced with PBS. After 
incubation,   cells   were   washed   once   with   PBS,   and 
incubated with PBS/Serum and PBS/Gelatin for 5 minutes 
each at 22°C. After incubation, a volume of 40 μL (8 
μg/mL) of Goat FITC-conjugated anti-mouse IgG (1:50 in 
the blocking buffer PBS/Gelatin; sc-2010, Santa Cruz, CA) 
was added, and cells were incubated in the dark for 1 
hour   at   37°C.   Cells   were   washed   twice   at   room 
temperature   with   PBS   (5   minutes   each),   and   the 
fluorescence was measured at 485 nm excitation 520 nm 
emission   wavelengths,   using   a   FLUOstar   OPTIMA 
microplate reader (BMG Labtechnologies, USA) according 
to the manufacturer’s instructions.
Western blotting
MCF-7 cells were plated in culture flasks and allowed to 
grow until 80% of confluence. Cells were treated with 
different doses of 2-cyclopenten-1-one for 4 hours. Whole 
cell extracts were prepared by lysing cells in ice-cold RIPA 
(Radio-Immunoprecipitation Assay) buffer (Santa Cruz 
Biotechnology,   CA)  containing   freshly   added   protease 
inhibitors provided with the RIPA lysis buffer kit for 30 
minutes on ice. Cells were disrupted and homogenized by 
passing through 21 gauge needle. After centrifugation at 
10,000g   for   10   minutes   at   4°C,   the   supernatant   was 
collected   and   protein   content   determined   using   a 
Bradford assay (Bio-Rad, USA). Supernatants were kept 
frozen at -80°C until analysis. Extracted proteins (100 μg) 
were heated at 100°C for 4-5 minutes in 2X SDS gel 
loading buffer (100 mM Tris-HCl (pH 6.8), 4% SDS, 20% 
glycerol, 200 mM dithiothreitol, and 0,2% bromophenol 
blue). Proteins were separated by SDS polyacrylamide gel 
electrophoresis on 10% separating gel and 5% stacking 
gel, and transferred on Immobilon-P PVDF membranes 
and immunoblotting of the cyclin D1 protein was carried 
out using the BM Chemiluminescence Blotting substrate 
(POD) kit. After overnight incubation in 50 mL solution 
1%, membranes were incubated with diluted anti-cyclin 
D1 antibody (1:250 with blocking solution 0.5%) for 1 hour 
at 22°C. After incubation with antibody, membranes were 
washed three times for 15 minutes each time with 50 mL 
of Tris buffered saline (TBS: 50 mM Tris base, 150 mM 
NaCl, pH 7,6) containing 0.05% Tween (TBS-Tween), and 
incubated for 1 hour at 22°C with POD-conjugated anti-
mouse antibody diluted 1:5000 in blocking solution 0.5%. 
After incubation, membranes were washed 4 times for 20 
minutes each time in 50 mL of PBS-Tween 0.05%, and then 
incubated for 60 seconds with the pre-mixed detection 
reagent (20 μL/cm
2 of membrane). Autoradiography was 
performed   using   Kodak   X-Omat   5000RA   film.   This 
experiment was repeated three times.
Cell proliferation
Cells were seeded in clear 96-well plates (Corning Costar, 
Fisher Scientific, USA) at a density of 10,000 cells/well. 
After 24 hours, the culture medium was replaced by fresh 
medium. 2-Cyclopenten-1-one was added to the cells in 
the   presence   of   10%   fetal   bovine   serum   at   a   final 
concentration varying from 150 to 1200 μg/mL and cells 
were   incubated   at   37°C   for   4   hours   in   a   5%   CO2 
atmosphere. In untreated control cells, cyclopentenone 
was replaced by an equal amount of sterile water. After 
incubation, cell number was evaluated using the MTT Cell 
Proliferation Assay (22).  Briefly, cells were rinsed twice 
with PBS and 50 μL of fresh culture medium was added to 
each well, followed by the addition of 8 μL of a solution of 
4 mg/mL MTT (Sigma-Aldrich, St-Louis, MO). After 2 h 
incubation, the purple formazan crystal was solubilized 
by adding 120 μL of lysis buffer (1 % HCl 12 N and 5% 
Triton X-100 in isopropanol), and the absorbance was 
measured   at   570   nm   on   a   SpectroMax   Microplate 
Spectrophotometer (Molecular Devices, Sunnyvale, CA, 
USA). This experiment was repeated twice.
Statistics
Statistical   analysis   of   differences   between   treatment 
groups was evaluated by  Student’s  t  test for unpaired 
observations using the Analysis Toolpak of Microsoft
Excel. P< 0.05 was considered significant.
RESULTS
Amount of cyclin D1 varies upon cell density
The biological model used to test the FICP method was 
based on the detection of the cell cycle protein cyclin D1 in 
MCF-7 cells. Cells were cultured and plated as described 
in Materials and Methods by varying the cell density from 
5000 to 20,000 cells per well. As shown in Fig. 1, the 
fluorescence   signal  significantly  increased   with   the 
amount of cells (p<0.01 and 0.001). These results showed 
that the immunoassay is able to detect a variation in the 
amount of a given protein based only on the number of 
cells.
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Inhibition of cyclin D1 protein expression by 
cyclopentenone
2-Cyclopenten-1-one is known to cause cell cycle arrest in 
G1 and down-regulate cyclin D1 protein expression in 
MCF-7   cells   (19,   23).  To   determine   whether   the 
fluorescence immunoassay FICP was able to specifically 
detect a variation in the amount of cyclin D1 protein we 
treated   the   cells   with   different   concentrations   of 
cyclopentenone for 4 hours. In these experiments, MCF-7 
cells were plated in 96-well microplates at a density of 
10,000 cells/well or in 75 cm
2 flasks at a concentration of 10 
x   10
6  cells/flask.   After   24   hours   plating,   the   culture 
medium was replaced by fresh medium supplemented 
with cyclopentenone at a final concentration varying from 
150 to 1200 μg/mL. After 4 hours incubation, cyclin D1 
expression   was   measured   by   either   the   fluorescence 
immunoassay or Western Blot as described in Materials 
and Methods. The results are summarized in Fig. 2. The 
amount of cyclin D1 protein detected by the fluorescence 
signal   inversely   decreased   with   the   concentration   of 
cyclopentenone. At cyclopentenone concentrations higher 
than 150 μg/mL, the amount of cyclin D1 protein was 
significantly decreased compared to control cultures, with 
maximum inhibition at 600 μg/mL (p<0.05 for 300 μg/mL 
and p<0.001 for 600 and 1200 μg/mL, Fig. 2A). Results 
obtained by immunoblot analysis showed a diminution in 
expression  of  cyclin   D1   protein  in   cells   treated   with 
cyclopentenone when compared to untreated control cells 
(Fig. 2B). Detection of cyclin D1 protein was clearly visible 
in untreated control cultures however no cyclin D1 bands 
were detected in cells treated with 150 μg/mL and higher 
concentrations of cyclopentenone. The intensity of the 
tubulin signal decreased at increasing concentrations of 
cyclopentenone   probably   due   to   the   increasing 
cytotoxicity   at   doses   higher   than   300   μg/mL   of 
cyclopentenone.
Cell proliferation inhibition
Since cyclopentenone causes an arrest in cell cycle and 
inhibits tumor cells proliferation (17-19) it was important 
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Fig.   1:   Effect   of   cell   density   on   the   signal   in 
immunofluorescence detection of cyclin D1 protein. MCF-7 cells 
were plated in a 96-well microplate at different cell densities as described 
in Materials and Methods. As negative control, the primary antibody was 
replaced by an equal amount of PBS. Results are representative of two 
separate experiments, each done in 12 replicates. Data shown represent 
the mean of 12 replicates ± SD from one experiment. * p< 0.01, ** p< 
0.001.
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Fig.   2:   Inhibition   of   cyclin   D1   protein   expression   by 
cyclopentenone. MCF-7 cells exposed to cyclopentenone and untreated 
cells were processed after 4 hours of treatment. (A) Amount of cyclin D1 
protein in each microwell was detected by immunofluorescence. Results 
are representative of four separate experiments, each done in 6 replicates. 
Data shown represent the mean of at least 5 replicates ± SD from one 
experiment. (B) CyclinD1 protein detection by Western blotting. Wells 1, 2, 
3, and 4 represent cells treated with 150 μg/mL, 300 μg/mL, 600 μg/mL, 
or 1200μg/mL of cyclopentenone, respectively. Well C represents untreated 
control cultures. Results are representative of the amount  of protein 
obtained   in   three   separate   experiments,   and   represent   a   single 
immunoblot. * p< 0.05, ** p< 0.001.
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to assess whether the diminution in the production of 
cyclin D1 observed in the fluorescence immunoassay and 
the Western Blot method was correlated with an inhibition 
in the proliferation of the cells. As shown in Fig. 3, the 
number of cells decreased in a dose-response manner with 
increasing concentration of cyclopentenone in the culture 
medium.
Specificity of the fluorescence immunoassay
To evaluate the specificity of the FICP assay, we next 
evaluated the effect of cyclopentenone on the expression 
of the cyclin dependent kinase (CDK) p21
CIP1/WAF1 protein. 
This   protein   was   chosen,   as   the   treatment   with 
cyclopentenone has resulted in an induction of its protein 
expression in tumor (17-19).  Therefore, we repeated the 
experiment   as   described   above,   and   investigated   the 
amount of p21
CIP1/WAF1  protein in parallel with those of 
cyclin D1 protein. The induction of p21
CIP1/WAF1 and cyclin 
D1 proteins were evaluated in separate wells of the same 
microplate. Results showed that a significant increase 
(p<0.01) in the amount of p21
CIP1/WAF1 protein was observed 
in cells treated with 300 and 600 μg/mL of cyclopentenone 
compared to untreated control cells (Fig. 4). At higher 
doses, such as 1200 μg/mL, amount of p21 decreases 
apparently due to toxicity of the compound. 
DISCUSSION
In this paper, we describe a method for detection of 
protein in cells plated in a 96-microwell that we called 
FICP  method  (Fluorescence  Immunoassay  for  Cellular 
Protein detection), which has potential applications for 
drug screening. FICP is an improvement in drug screening 
techniques because it allows quantitative determination of 
biological effects of test compounds directly on targeted 
proteins in the cell environment. In addition, biological 
effects of a specific compound on protein levels can be 
calculated   (%   of   inhibition)   and   statistics   can   be 
performed by using this method. 
The FICP method was adapted from standard protocols 
for immunofluorescence microscopy which are used for 
detection  of  proteins  from  cells   fixed   on  microscopic 
slides. The number of rinses was diminished from 3 to 2 at 
each step to decrease the risk of cell loss and shorten the 
duration of the assay. The major advantage provided by 
the FICP is the possibility of rapidly detect proteins in 
non-lysed cells plated in a 96-well microplate. The FICP 
method can be used for testing different compounds at 
different doses in a same plate by using small amounts of 
drug, leading to the cost effective investigation of very 
expensive drugs such as antisense oligonucleotides or 
small interfering RNAs.
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Fig.   3:   Effect   of   cyclopentenone   on   MCF-7   cell   proliferation. 
Cells were plated in 96- well plates at a density of 10,000 cells per well. 
Viable cells were measured using the MTT Cell Proliferation Assay 4 hours 
after treatment with increasing doses of cyclopentenone. Data shown 
represent mean of 12 replicates ± SD from two separate experiments, each 
done in 6 replicates.
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Fig.   4:   Activation   of   p21
CIP1/WAF1  protein   expression   in   MCF-7 
cells by cyclopentenone.  Untreated and treated cells were processed 
after 4 hours of treatment and amount of p21
CIP1/WAF1  protein in each 
microwell was detected by immunofluorescence. Results are representative 
of three separate experiments done in triplicate. Each bar represents the 
mean of at least 3 replicates ± SD from one experiment. * p < 0.01.
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The immunofluorescence assay described in this study 
can be optimized to detect more than one protein at a time 
which allows studies of expression levels of two or more 
proteins in the same experimental conditions, saving time, 
precious test compounds and cells. Using FICP, we have 
clearly delineated cyclopentenone dual biological effect on 
cell cycle by quantifying inhibition of cyclin D1 expression 
and induction of p21 on a same microplate. Variation and 
amount of protein values obtained here are expected as 
previously described (19, 23). These results show that the 
fluorescence immunoassay FICP is able to specifically 
detect variations in expression of different proteins into 
cells treated with the same compound.
In Table 1, the FICP method is compared with Western 
blot procedure respective to sensitivity, reproducibility 
and specificity. It is obvious that FICP presents several 
advantages and is superior for many characteristics over 
the immunoblotting procedure. FICP is as specific as 
immunoblotting but is 5 to 10 times more sensitive and 
more reproducible than Western blot procedure, based on 
the amount of protein (Table 1). In this study, the FICP 
was able to detect a dose-response diminution of protein 
expression where immunoblotting failed to do it probably 
because of the limitation on the amount of total proteins 
that can be loaded on the electrophoretic gel or the loss of 
cyclin D1 protein during the cell washes in the Western 
blot   procedure,   due   in   part   to   cytotoxicity-induced 
membrane permeability. In FICP, cells are directly fixed 
after incubation with cyclopentenone allowing a more 
precise detection of protein levels. These results suggest 
that the FICP is more suited to detect variations in protein 
expression. In addition, by using FICP, protein detection 
can be achieved by using 1000 times less cells which may 
represent   an   important   advantage   when   using,   for 
instance, primary cells.
One limitation of the FICP method described here could 
be the difficulty to detect proteins expressed at very low 
levels with low-affinity antibodies due to the sensitivity of 
the multiwell fluorescence plate reader. Nevertheless, this 
limitation can be overcome by measuring signal by a 
fluorescence-labelled primary antibody, thus avoiding the 
use of a secondary antibody and cutting down as well cost 
and needed time period for this procedure. The use of 
fluorochromes such as Alexa Fluor series or cy3 CYBR 
gold that have been recently made available, may also 
improve   the   immunofluorescence   assay   method   FICP 
described in this study and should be tested.
In conclusion, we have developed a microwell cell-based 
immunoassay that is a sensitive and accurate alternative 
to   immunoblot   analysis   for   rapid   and   inexpensive 
screening   of   large   numbers   of   cell   samples.   FICP 
constitutes a screening assay with relative measurement of 
protein abundance/well. FICP has been developed in 96-
well plates but could theoretically be adapted to 384-well 
plates and other formats, as well as robots use. The FICP 
method described here provides a rapid, simple, specific, 
sensitive,   and   reliable   method   for   cellular   protein 
detection and we believe this method could be very useful 
for detecting variations in protein expression and for drug 
development.   More   has   to   be   done   to   determine 
reproducibility, variance, and linearity of the dynamics of 
the assay, to perform similar evaluation on other human 
cell lines and evaluate detection of more than two proteins 
per assay. Finally, this method also allows visualization of 
the   targeted   protein   into   cells,   as   classical 
immunofluorescence   methods,   by   microscopic 
examinations of cells plated in the microwell plates.
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